Call for Abstract

10th International Conference on Genomics and Molecular Biology, will be organized around the theme “Advanced Approaches In Genomics and Molecular Biology”

Genomics 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Genomics 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Genomics is the investigation of genomes, the entire arrangement of hereditary material inside a life form. Genomics includes the sequencing and examination of genomes. Genomics is additionally worried about the structure, capacity, examination, and advancement of genomes. As opposed to hereditary qualities, which alludes to the investigation of individual qualities and their parts in legacy, genomics utilizes high throughput DNA sequencing and bioinformatics to amass, and examine the capacity and structure of whole genomes.

Cancer Genomics is the study of genetic mutations responsible for cancer, using genome sequencing and bioinformatics. Clinical genomics is to improve cancer treatment and outcomes lies in determining which sets of genes and gene interactions affect different subsets of cancers. International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers.

  • Track 2-1Personal genome screening
  • Track 2-2Emerging Themes in Cancer Genomics
  • Track 2-3Cancer Biopsy
  • Track 2-4Cancer Genome Therapy
  • Track 2-5 Epigenetics & Cancer Genomics
  • Track 2-6 Cancer Nanotechnology
  • Track 2-7 Hormone-Dependent Cancers
  • Track 2-8 New Frontiers in Gene Editing
  • Track 2-9 Big Data in Cancer Genomics
  • Track 2-10 Stem Cells- Cancer
  • Track 2-11Cancer Nanotheranostics
  • Track 2-12Cancer Genome Analysis
  • Track 2-13Cancer Genome Sequencing
  • Track 2-14Cancer Genome Alignment
  • Track 2-15Cancer-related micro RNA and m-RNA
  • Track 2-16 Tumor Heterogenecity
  • Track 2-17 Cancer Genomics and Proteomics impact factor
  • Track 2-18Molecular underpinnings of therapeutic targets
  • Track 2-19Abberant DNA methylation in cancer
  • Track 2-20Cell Fate in Cancer
Molecular biology concerns the molecular basis of biological activity between the various systems of a cell, including the interactions between the different types of DNA, RNA and proteins and their biosynthesis, and studies how these interactions are regulated. It has many applications like in gene finding, molecular mechanisms of diseases and its therapeutic approaches by cloning, expression and regulation of gene. Research area includes gene expression, epigenetics and chromatin structure and function, RNA processing, functions of non-coding RNAs, transcription. Nowadays, Most advaced researches are going on these topics: Molecular biologyDNA replication, repair and recombination, Transcription, RNA processing, Post-translational modification, proteomics, Mutation, Site-directed mutagenesis, Epigenetics, chromatin structure and function, Molecular mechanisms of diseases.
  • DNA replication, repair and recombination
  • Transcription and Gene Expression
  • RNA processing
  • Post-translational modification, proteomics
  • Mutation, Site-directed mutagenesis
  • Epigenetics, chromatin structure and function
  • Molecular mechanisms of diseases
  • Track 3-1DNA replication, repair and recombination
  • Track 3-2Transcription and Gene Expression
  • Track 3-3RNA processing
  • Track 3-4Post-translational modification, proteomics
  • Track 3-5Mutation, Site-directed mutagenesis
  • Track 3-6Epigenetics, chromatin structure and function
  • Track 3-7Molecular mechanisms of diseases

National Science Foundation (NSF) announces its intention to continue to support plant genome research through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) awards from the National Science Foundation (NSF) that NSF offers supplements to support research collaboration with scientist sin developing countries. The intent of Developing Country Collaborations in Plant Genome Research (DCC-PGR) awards is to support collaborative research linking U.S. researchers with partners from developing countries to solve problems of mutual interest in agriculture, energy and the environment, while placing U.S. and international researchers at the center of a global network of scientific excellence.

  • Track 4-1Plant Stem Cells
  • Track 4-2Single cell Genomics
  • Track 4-3Weed Science
  • Track 4-4 Rice Genome
  • Track 4-5Plant Pathology
  • Track 4-6Cereals and Crops
  • Track 4-7 Plant Tissue Culture
  • Track 4-8Plant Genomics in World Economy
  • Track 4-9 Mendidian Genetics
  • Track 4-10Plant Genomics Applications
  • Track 4-11Plant Science
  • Track 4-12Bioinformatics
  • Track 4-13Plant Genome Sequencing
  • Track 4-14Plant Epigenetics
  • Track 4-15Transgenic Plants
  • Track 4-16Plant Breeding
  • Track 4-17Plant Physiology

Structural biology seeks to provide a complete and coherent picture of biological phenomena at the molecular and atomic level. The goals of structural biology include developing a comprehensive understanding of the molecular shapes and forms embraced by biological macromolecules and extending this knowledge to understand how different molecular architectures are used to perform the chemical reactions that are central to life.Most recent topics related to structural biology are:Structural BiochemistryStructure and Function Determination, Hybrid Approaches for Structure Prediction, Structural Biology In Cancer ResearchComputational Approaches in Structural BiologyStrucutural Biology Databases.

 

  • Hybrid Approches for Structure Prediction
  • Structural Biology In Cancer Research
  • Computational Approaches in Structural Biology
  • Strucutural Biology Databases
  • Signalling Biology
  • Molecular Modeling and Drug Designing
  • Recent Advances In Structural Biology
  • Structural Biochemistry
  • Structure and Function Determination
  • Track 5-1Hybrid Approches for Structure Prediction
  • Track 5-2Structural Biology In Cancer Research
  • Track 5-3Computational Approaches in Structural Biology
  • Track 5-4Strucutural Biology Databases
  • Track 5-5Signalling Biology
  • Track 5-6Molecular Modeling and Drug Designing
  • Track 5-7Recent Advances In Structural Biology
  • Track 5-8Structural Biochemistry
  • Track 5-9Structure and Function Determination

Stem cells are cells originate in all multi-cellular organisms. They were isolated in mice in 1981 and in humans in 1998. In humans there are several types of stem cells, each with variable levels of potency. Stem cell treatments are a type of cell therapy that introduces new cells into adult bodies for possible treatment of cancerdiabetes, neurological disorders and other medical conditions. Stem cells have been used to repair tissue damaged by disease or age. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm, but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

 

 

  • Embryonic Stem Cells
  • Mesenchymal Stem Cells
  • Regulation of Stem Cells
  • Dedifferentiation, transdifferentiation and reprogramming
  • Stem Cells in Disease Modeling and Therapy
  • Stem Cell Treatments
  • Stem Cell Transplant
  • Stem Cell Technologies
  • Cancer Stem Cells
  • Stem Cells: Controversies & Regulation
  • Track 6-1Embryonic Stem Cells
  • Track 6-2Mesenchymal Stem Cells
  • Track 6-3Regulation of Stem Cells
  • Track 6-4Dedifferentiation, transdifferentiation and reprogramming
  • Track 6-5Stem Cells in Disease Modeling and Therapy
  • Track 6-6Stem Cell Treatments
  • Track 6-7Stem Cell Transplant
  • Track 6-8Stem Cell Technologies
  • Track 6-9Cancer Stem Cells
  • Track 6-10Stem Cells: Controversies & Regulation
  • Track 7-1Cellular and Molecular Genetics
  • Track 7-2 Drug Discovery
  • Track 7-3Neurodevelopmental Disorders
  • Track 7-4 Transplantation
  • Track 7-5 Cytogenetics
  • Track 7-6Congenital Disorders
  • Track 7-7 Diabetes and Obesity
  • Track 7-8Cancer and Genome Integrity
  • Track 7-9 Stem cells and Regenerative Medicine
  • Track 7-10Genomics: Disease and Evolution
  • Track 7-11 Bioinformatics in Human Genetics

Bioinformatics the science of collecting and analyzing complex biological data such as genetic codes. Molecular medicine requires the integration and analysis of genomic, molecular, cellular, as well as clinical data and it thus offers a remarkable set of challenges to bioinformatics. Bioinformatics nowadays has an essential role both, in deciphering genomic, transcriptomic, and proteomic data generated by high-throughput experimental technologies, and in organizing information gathered from traditional biology and medicine. Research Centers for Bioinformatics are: National Centers for Biomedical Computing,  National Center for Simulation of Biological Structures, National Center for the Multiscale Analysis of Genomic and Cellular Networks, National Alliance for Medical Image Computing (NA-MIC), National Center for Biomedical Ontology (NCBO) at Stanford University, Integrate Data for Analysis, Anonymization, and Sharing (IDASH) at the University of California, San Diego. The Canadian government is also ponying up cash for omics research, with the Canada Foundation for Innovation backing several projects as part of a C$30.4 million ($27.6 million) investment in academic research. McGill University scooped the joint-biggest award for a project, C$400,000, to advance its single-cell genomics infrastructure.

  • Track 8-1Computational genomics and computational proteomics
  • Track 8-2In vitro models for drug development
  • Track 8-3Molecular modelling and drug designing
  • Track 8-4Sequence analysis and allignment
  • Track 8-5 Tools for functional and comparative genomics and proteomics
  • Track 8-6Systems genetics and systems biology
  • Track 8-7 BioData mining
  • Cell Organelles: Function and Dysfunction
  • Dynamic Control of Cell Shape and Polarity
  • Nuclear Structure, Dynamics and Function
  • Epigenetic Control of Cell Fate
  • Cell Division and Cell Cycle
  • Cell Death, Autophagy, Cell Stress
  • Cell Signalling and Intracellular Trafficking
  • Cell Biology of Ageing
  • Cell Biology of Metabolic Diseases
  • Cell Biomechanics and Regulations
  • Track 9-1Cell Organelles: Function and Dysfunction
  • Track 9-2Cell Biomechanics and Regulations
  • Track 9-3Dynamic Control of Cell Shape and Polarity
  • Track 9-4Nuclear Structure, Dynamics and Function
  • Track 9-5Epigenetic Control of Cell Fate
  • Track 9-6Cell Division and Cell Cycle
  • Track 9-7Cell Death, Autophagy, Cell Stress
  • Track 9-8Cell Signalling and Intracellular Trafficking
  • Track 9-9Cell Biology of Ageing
  • Track 9-10Cell Biology of Metabolic Diseases
  • Track 9-11Cell Biomechanics and Regulations

Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.

  • Track 10-1Exome sequencing
  • Track 10-2 Hybrid sequencing approach
  • Track 10-3Sequencing Technologies
  • Track 10-4 Cell and Gene Therapy
  • Track 10-5NGS Data Analysis
  • Track 10-6Role of NGS in Cancer Drug Development
  • Track 10-7 Clinical Applications of NGS
  • Track 10-8 Advances of NGS in Therapeutics

MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.

  • Track 11-1 Single Cell MicroRNA Analysis
  • Track 11-2 PCR analysis of blood and saliva specific microRNA markers
  • Track 11-3 Ion mobility-mass spectrometry to microRNA analysis
  • Track 11-4Single Molecule Genomics
  • Track 11-5microRNA expression analysis
  • Track 11-6 MicroRNA in Cancer
  • Track 11-7miRNA expression
  • Track 11-8 MicroRNA expression
  • Track 11-9miRNA Biogenesis
  • Track 11-10Meta-analysis of microRNA
  • Track 11-11Visual Detection of microRNA

First, the vast numbers of species and the much larger size of some genomes makes the entire sequencing of all genomes a non-optimal approach for understanding genome structure. Second, within a given species most individuals are genetically distinct in a number of ways. What does it actually mean, for example, to "sequence a human genome"? The genomes of two individuals who are genetically distinct differ with respect to DNA sequence by definition. These two problems, and the potential for other novel applications, have given rise to new approaches which, taken together, constitute the field of comparative genomics.

  • Track 12-1Paleogenomics
  • Track 12-2Gene Rearrangement
  • Track 12-3Gene cluster
  • Track 12-4Algorithms for genome evolution
  • Track 12-5Gene Order and Phylogenetic reconstruction
  • Track 12-6Gene Annotation
  • Track 12-7Genomic Variation
  • Track 12-8Comparative tools for genome assembly
  • Track 12-9Cancer evolutionary genomics
  • Track 12-10Geno type

Functional Genomics use vast wealth of data produced by genomic and transcriptomic projectstodescribe gene functions and interactions. Trends in Functional Genomics are Affymetrix emerged as an early innovator in this area by inventing a practical way to analyze gene function as a system. NimbleGen Systems and Febit, are developing fabricated microarrays that are produced using a micro mirror based, mask less system. Texas Instruments developed the micro mirrors that direct light onto specific areas of a grid to activate the DNA synthesis reaction and elongate oligonucleotide chains. BioRobotics, Genetix, Genomic Solutions, and others offer a wide range of products needed to manufacture arrays. Applied Biosystems, PerkinElmer, Qiagen, and Zymark Corporation manufacture automated work stations and robotic systems to fully automate routine laboratory procedures. Invitrogen, PanVera, and Roche Applied Science, have developed complete biochemical and cellular assays that are compatible with high throughput systems Applied Bio systems offers a wide range of core instruments and systems necessary for functional genomics, such as DNA sequencers and synthesizers.

American Society of Transplant Surgeons Up to $100,000 per year ($50,000 in cash and up to $50,000 in-kind) for 2 years. For purposes of this grant, in-kind support is limited to the cost of assays. Genomics Market in the US 2014-2018 and Global Genomics Market 2014-2018 research reports to its store.  Functional Genomics market in the US is forecast to grow at a CAGR of 7.28% over the period 2013-2018 whereas the global genomics industry is projected to grow at 11.21% CAGR during the same time. Global genomics market research for 2014-2018 considers the revenue generated by vendors through the sales of instruments, consumables, and services for genomics to arrive at a ranking of the leading vendors of the market, and to calculate the market size.

  • Track 13-1Structural genomics
  • Track 13-2Phytochemical genomics
  • Track 13-3Chemical genomics
  • Track 13-4Biochemistry, biotechnology, and genomics
  • Track 13-5Genomic Sequencing
  • Track 13-6Metabolomics
  • Track 13-7Microbial functional genomics
  • Track 13-8Functional Genomics and Molecular Analysis
  • Track 13-9Functional genomics of pain in drug development
  • Track 13-10Comparative Functional Genomics
  • Track 13-11Patterns and determinants of variation in functional genomics
  • Track 13-12 Functional genomics and bioinformatics
  • Track 13-13Genome Analysis
  • Track 13-14CRSPR/CAS9 system for Genome Editing
  • Track 13-15 Application genomics
  • Track 13-16Mitochondrial Genomics

Pharmacogenomics  is the study of the role of genetics in drug response. Computational advances in Pharmacogenomics has proven to be a blessing in research. A large amount of research in the biomedical sciences regarding Pharmacogenomics as of late stems from combinatorial chemistry,[53] genomic mining, omic technologies and high throughput screening. In order for the field to grow rich knowledge enterprises and business must work more closely together and adopt simulation strategies. Major Universities dealing Pharmacogenomics are:  Harvard University, US, , University of Cambridge, UK, National University of Singapore, Singapore, University of Oxford, UK, Karolinska Institute, Sweden, Monash University, Australia, Imperial College London, UK, University of Tokyo, Japan, University of Melbourne, Australia, University of Michigan, US.

  • Track 14-1Translational Pharmacogenomics
  • Track 14-2Pharmacogenitics & Individualized therapy
  • Track 14-3Cancer Pharmacogenomics
  • Track 14-4Pharmacogenomics
  • Track 14-5 Molecular diagnostics
  • Track 14-6 Molecular-targeted interventions including gene therapy
  • Track 14-7Biological and small molecule therapeutics
  • Track 14-8Biomarker translation and testing
  • Track 14-9 Toxicogenomics
  • Track 14-10 Nutrigenomics
  • Track 14-11Applications of NGS to Pharmacogenomics
  • Track 14-12Pharmacogenomics in Clinical Therapeutics

Genomic Medicine as "an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.

  • Track 16-1Biomarkers in Genomic Medicine
  • Track 16-2Genomics & epigenomics of disease
  • Track 16-3 Pharmacogenomics & personalized medicine
  • Track 16-4Genomic epidemiology & public health genomics
  • Track 16-5Proteomics & metabolomics in medicine
  • Track 16-6Systems medicine & informatics

Biomarker is a measurable indicator of the severity or presence of some disease state.
Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 2010. The accelerating pace of activity in this area is further underlined by a cursory review of the publication space, where the number of relevant scientific articles generated annually has doubled from 20,000 to 40,000 over the past decade. AACR, in partnership with the Food and Drug Administration (FDA) and National Cancer Institute (NCI), formed the AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC) to accelerate the translation of cancer therapeutics into the clinic by shaping the processes for the effective development of validated biomarkers and their use in clinical trials for maximum patient benefit.

  • Track 17-1Cancer Biomarkers
  • Track 17-2 Clinical & Transaltional Biomarkers in Drug Discovery
  • Track 17-3 Chromosomal Biomarkers of Genomics
  • Track 17-4Molecular Imaging Biomarkers
  • Track 17-5Bigdata to Advance Personalized Medicine

Microbial Genomics- applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes in microbes. Genetics Otago is the largest center for advanced Genetics research in Australia. Focus on 7 main themes, which cover the full spectrum of genetics research. The Centre of Microbial and Plant Genetics (CMPG) was founded in 1953 discoverer of crossing-over sites in chromosomes of meiotic cells. A number of important scientific opportunities exist in genome analysis related to microbiology. Current genome projects, however, do not adequately represent the full range of microorganisms. A microbial genome program based on rational priorities is needed to make strategic decisions about the appropriation and distribution of funding and resources. OpGen filed plans with the U.S. Securities and Exchange Commission to sell 3.75 million shares in an initial public offering with the goal of securing up to $35.2 million. The Gaithersburg, Md.-based microbial genetics analysis company said it will use the money as working capital and to support increased sales and marketing efforts for its genetic tests for multidrug resistance organisms.

  • Track 18-1Bacterial and viral Genomics
  • Track 18-2 Microbiomics
  • Track 18-3Microbial functional genomics
  • Track 18-4Microbial genetics
  • Track 18-5Ecoli Genome and Genomics
  • Track 18-6Regulation of genes in livestock
  • Track 18-7Annotated sequences of cattle
  • Track 18-8Buffalo and poultry genomes
  • Track 19-1Protein Expression and Analysis
  • Track 19-2 Integrating Transcriptomics and Proteomics
  • Track 19-3 Neuroproteomics & Neurometabolomics
  • Track 19-4 Immunoproteomics
  • Track 19-5Cancer and Clinical proteomics
  • Track 19-6 Food and Nutritional Proteomics
  • Track 19-7 Plant Proteomics and Applications
  • Track 19-8 Proteomics for Bioinformatics
  • Track 19-9Proteomics in Computational and Systems Biology
  • Track 19-10 Proteomics in Personalized Medicine
  • Track 19-11 Protein Biochemistry and Proteomics
  • Track 19-12Business Trends in Proteomics
  • Track 19-13 Proteomics from Discovery to Function
  • Track 19-14 Mass Spectrometry in Proteome Research
  • Track 19-15Proteomics Database
  • Track 19-16 Statistical Advances in Biomedical Sciences

Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information or genome of living organisms. The CRISPR-cas9 system makes gene editing in many organisms and cells like our own egg, sperm or embryo — more efficient, accessible and simple than ever before. These groundbreaking capabilities have spawned discussions surrounding the ethics and applications of the new system, and have garnered significant attention around the world to ensure ethically correct usage

  • Track 20-1 Human Genome Engineering
  • Track 20-2Multiplex Automated Genomic Engineering
  • Track 20-3Induced Pluripotent Stem Cell Technology
  • Track 20-4Targeted Genome Editing
  • Track 20-5Advances in Genome Editing
  • Track 20-6Genome Profiling
  • Track 20-7 CRISPR/CAS Revolution in Genome Engineering
  • Track 20-8Gene Editing using CRISPR/Cas9
  • Track 20-9Plant Genome Engineering and Genome Reprogramming

Genomics research holds the key to meeting many of the challenges of the coming years. At the moment, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is really hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.

  • Track 21-1Genetic epidemiology and pharmacoepidemiology
  • Track 21-2Genetic counseling
  • Track 21-3Phenomics
  • Track 21-4Synthetic biology and bioengineering
  • Track 21-5Translational genetics and genomics
  • Track 21-6 Molecular pharming
  • Track 21-7 Genomics in ageing

Genomics is the study of the genetic material or genomes of an organism. Analysts forecast the Global Genomics market will grow at a CAGR of 11.21% over the period 2013-2018. According to the report, the most important driver of the market is an increase in the demand for consumables. The growing adoption of genetic testing for various applications, especially in regions such as the APAC, and an increase in genetic testing volumes in North America and Western Europe is increasing the demand for consumables.

  • Track 22-1 Genomics Asia
  • Track 22-2Genomics North America
  • Track 22-3Genomics South America
  • Track 22-4Genomics Australia
  • Track 22-5 Genomics Africa
  • Track 22-6 Genomics Europe